Flattened Working-Memory Development Did Not Mean Scores Were Lower at Every Age

The youth study reported a different age-related working-memory trajectory after cannabis initiation. Its modeled groups were not uniformly separated in the same direction across all ages.

The reported pattern changed with age

The authors describe better estimated working-memory performance in the cannabis-use group at younger ages, no group difference around ages fifteen to sixteen, and a worse comparison at seventeen. Their central interpretation was that the cannabis-use group did not show the same age-related improvement as controls.

A slope and an absolute score answer different questions

A group can improve more slowly from a higher starting level without being lower throughout follow-up. Conversely, a favorable younger-age comparison does not erase a later unfavorable trajectory. The study’s age interaction needs the direction and developmental context attached, rather than being reduced to a statement that every young user performed worse at every assessment.

The pattern was observational

Measured covariates and repeated observations strengthen the analysis but do not establish the cause of each individual’s developmental course. The use indicator also reflected identified initiation history, not acute intoxication at every visit. The result supports a population-level concern about trajectories. It does not determine a particular child’s prognosis or establish irreversible decline from a single score.

Related analysis: the source’s broader findings and limitations.

Research cited

Wade and colleagues (2026). Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us